NEW YORK, April 18 (GenomeWeb News) - The National Cancer Institute's Cohort Consortium will use genotyping technology and protocols from Applied Biosystems to study the genetics of breast and prostate cancer, ABI said today.
The project, which combines six large prospective cohort studies that include more than 6,000 breast cancer and 8,000 prostate cancer patients, will make use of ABI's TaqMan SNP genotyping assays and 7,900HT real-time PCR systems to identify inherited gene variants that may contribute to the development of the two cancers. The SNP genotyping assays were designed by Applied Biosystems and will be made public to researchers.
Preliminary results from a first study by the Cohort Consortium started in 2003, entitled "Breast and Prostate Cancer and Hormone-Related Gene Variants Study," will be presented this week at the AACR meeting in
The NCI Cohort Consortium is a collaboration involving six American and European prospective cohort studies totaling 897,000 participants, three genomic facilities, and six genotyping centers.